|1.||Ambite-Quesada, Silvia: 5 articles (12/2013 - 10/2011)|
|2.||Fernández-de-las-Peñas, César: 4 articles (12/2013 - 10/2011)|
|3.||Nikolac, Matea: 4 articles (01/2012 - 04/2010)|
|4.||Pivac, Nela: 4 articles (01/2012 - 04/2010)|
|5.||Skorpen, Frank: 4 articles (01/2008 - 07/2005)|
|6.||Ortega-Santiago, Ricardo: 3 articles (12/2013 - 10/2011)|
|7.||Borovecki, Fran: 3 articles (01/2012 - 04/2010)|
|8.||Gil-Crujera, Antonio: 2 articles (12/2013 - 11/2012)|
|9.||Pregelj, Peter: 2 articles (09/2013 - 02/2011)|
|10.||Paska, Alja Videtič: 2 articles (09/2013 - 02/2011)|
07/30/2014 - "EMT markers and p-Met/Met were assayed by immunohistochemistry in tumor samples. "
02/01/2014 - "The results suggested a significant association between the Thr241Met polymorphism in XRCC3 gene and cancer risk in Chinese mainland populations (Met/Met + Thr/Met vs. Thr/Thr: OR = 1.25, 95 % CI = 1.02-1.54, P = 0.04). "
01/01/2009 - "MET (Met proto-oncogene) activation either by gene amplification or mutation is implicated in various types of human cancers. "
10/01/2006 - "The subgroup and meta-regression analysis demonstrated different scenarios concerning the XRCC3 Met/Met genotype's role in cancer susceptibility for different subgroups. "
10/01/2006 - "Overall, individuals carrying the XRCC3 Met/Met genotype showed a small cancer risk under a recessive genetic model. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
06/01/2012 - "Individuals carrying XRCC1 Gln/Gln, Thr/Met and Met/Met genotypes positively associated with 2.78-, 2.86- and 3.0-fold death risk of colorectal cancer. "
02/01/2005 - "For T439M, the Thr/Met genotype [odds ratio (OR) = 2.03, 95% confidence interval (CI) 1.04-3.98] and Thr/Met and Met/Met genotypes combined (OR = 2.37, 95% CI 1.23-4.56) demonstrated significant association with the development of colorectal cancer after adjusting for age, gender and smoking status. "
06/01/2004 - "Cancer occurrence was strongly associated with the XRCC3 Met/Met polymorphic variant (OR = 9.45; (95% CI 8.77-11.65)), whereas Thr/Thr and Thr/Met variants were associated with significant reduction in colorectal cancer risk (OR = 0.16; 95% CI 0-0.26 and OR = 0.26; 95% CI 0.25-0.27, respectively). "
08/01/2010 - "Subjective sleepiness and EEG markers of sleep homeostasis in wakefulness and sleep were equally affected by sleep deprivation in Val/Val and Met/Met allele carriers (placebo condition). "
03/01/2009 - "Two-time 100 mg modafinil potently improved vigor and well-being, and maintained baseline performance with respect to executive functioning and vigilant attention throughout sleep deprivation in Val/Val genotype subjects but was hardly effective in subjects with the Met/Met genotype. "
08/01/2015 - "Modafinil maintained executive functioning performance and vigilant attention throughout sleep deprivation in subjects with Val/Val genotype, but less in those with Met/Met genotype. "
|4.||Schizophrenia (Dementia Praecox)
10/01/2009 - "The homozygous carriers Met/Met were over-represented in the schizophrenia group (13/31, 41.9%), compared to controls (2/19, 10.5%). "
11/25/2005 - "The low-activity Met allele and Met/Met genotype were more frequent in OCD men than in schizophrenia-OCD and control individuals. "
05/09/2011 - "This study tests the hypothesis that Met/Met patients display more episodes of aggression and violent behaviour than Val/Val patients in a 6 year follow-up cohort of subjects with schizophrenia in contact with the South-Verona Community-based Mental Health Service. "
10/01/2014 - "However, no significant difference among Val/Val, Val/Met and Met/Met on the TMT-A and B in control subjects and patients with schizophrenia was detected. "
04/01/2012 - "The Met/Met genotype of BDNF Val66Met variant may be a risk factor for symptoms in first episode schizophrenia patients."
12/01/2013 - "This study suggests that the Val158Met polymorphism is associated with the presence of pain in MS, but it is not a risk factor for MS itself because the presence of the Met/Met genotype was more prevalent in those patients with pain. "
11/01/2014 - "Specifically, SCD patients with the DRD3 homozygote genotypes, COMT 158 Met allele or Met/Met genotype, are more likely to have acute care utilization, an indicator of acute pain. "
02/01/2014 - "Spontaneous moderate to severe pain was more likely to be associated with COMT Met/Met genotype. "
01/01/2014 - "Neonatal pain (adjusted for clinical confounders) and COMT Met/Met genotype were associated with SLC6A4 promoter methylation in very preterm children at 7 years (p = 0.001). "
12/01/2013 - "When we differentiate MS patients with pain and those without pain, the prevalence of Val158Met genotypes was significantly different (χ2 = 9,610, P = .046): Patients experiencing pain exhibited higher prevalence of Met/Met genotype than those without pain and healthy controls. "
|3.||Brain-Derived Neurotrophic Factor (BDNF)
|6.||Cyclooxygenase 2 (Cyclooxygenase-2)
|8.||Proteins (Proteins, Gene)
|9.||Hepatocyte Growth Factor (Growth Factor, Hepatocyte)
|10.||Catechol O-Methyltransferase (Methyltransferase, Catechol)
|1.||Prostheses and Implants (Prosthesis)
|2.||Heterologous Transplantation (Xenotransplantation)